Earnings preview: Medtronic to see profits bounce back in Q3?
This article was originally published in Clinica
Medtronic is reporting its third-quarter results on 19 February, with analysts predicting Q3 sales of $4.03 billion, up 3% year-on-year, and profit of $0.91 per share, also up 3% on earnings of $0.88 per diluted share in Q3 2012.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.